A Meta-analysis of Platinum Plus Docetaxel or Vinorelbine in the First-line Treatment of Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2014.04.07
- VernacularTitle:铂类联合多西他赛或长春瑞滨一线治疗晚期非小细胞肺癌的meta分析
- Author:
LIU TAISHENG
1
;
WU HUA
;
ZHUANG XIANMIAN
;
LU DI
;
CAI RUIJUN
;
WANG WUJUN
Author Information
1. 南方医科大学南方医院胸心血管外科
- Keywords:
Docetaxel;
Vinorelbine;
Platinum;
Lung neoplasms;
Meta-analysis
- From:
Chinese Journal of Lung Cancer
2014;(4):327-335
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Platinum plus a third-generation agent doublet chemotherapy is the stan-dard regimen and ifrst-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). hTe aim of this study is to evaluate the effcacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. Methods We searched the PubMed, EMBASE, Cochrane Library, CNKI, CBM, VIP, and WanFang databases for randomized controlled trials (RCTs), in which DP regimen was compared with VP regimen. A quality assessment of qualiifed RCTs was performed according to Cochrane Handbook 5.1.0, and Stata 12.0 was used to per-form meta-analysis. Results Seven RCTs involving 2,318 patients were included. Meta-analysis results indicated that the DP regimen increased the two-year survival rate (HR=0.887, 95%CI:0.810-0.972, P=0.010), response rate (RR=1.276, 95%CI:1.107-1.450, P=0.001), and diarrhea rate (RR=3.134, 95%CI:1.918-5.121, P<0.001) compared with the VP regimen. Anemia rate was also reduced (RR=0.386, 95%CI:0.311-0.478, P<0.001). No statistical differences were observed between DP and VP regimens in terms of one-year survival rate, leukopenia, neutropenia, thrombocytopenia, anorexia, nausea, and vomiting. Conclusion DP regimen reduced the rate of anemia and increased the rate of diarrhea, two-year survival rate, and response rate. hTerefore, DP regimen may be a more effective option as a ifrst-line treatment for advanced NSCLC compared with VP regimen.
